Beatrice Melin1, Robert Jenkins. 1. aDepartment of Radiation Sciences, Oncology, Umeå University, Sweden bDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester Minnesota, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to describe the recent knowledge gathered from the identification of seven genomic regions that have been linked to the risk of developing malignant glioma. RECENT FINDINGS: The recent novel discoveries in fine mapping and genotype-phenotype studies will be highlighted. Through imputation and next-generation sequencing a novel genetic variant, rs55705857, with a strong association at 8q24 has been discovered and validated in two studies. This locus is specifically associated with IDH1-mutated and IDH2-mutated tumors and oligodendroglial tumors, albeit the specific mechanism of tumor development is not understood. The genetic variants associated with the risk of glioma in the EGFR gene have also been associated with specific somatic aberrations, including loss at the CDKN2A/B locus and allele specific loss of EGFR in the tumors. A specific TP53 low frequency variant has also been associated with glioma risk and validated in a separate data set. The genetic risk in the telomere regulating genes TERT and RTEL appear to be associated with higher grade tumors without IDH mutations. SUMMARY: The link of genetic loci to specific tumor subtypes may have relevance for understanding glioma biology, and for developing new diagnostic tools and targeted therapy for glioma.
PURPOSE OF REVIEW: The purpose of this review is to describe the recent knowledge gathered from the identification of seven genomic regions that have been linked to the risk of developing malignant glioma. RECENT FINDINGS: The recent novel discoveries in fine mapping and genotype-phenotype studies will be highlighted. Through imputation and next-generation sequencing a novel genetic variant, rs55705857, with a strong association at 8q24 has been discovered and validated in two studies. This locus is specifically associated with IDH1-mutated and IDH2-mutated tumors and oligodendroglial tumors, albeit the specific mechanism of tumor development is not understood. The genetic variants associated with the risk of glioma in the EGFR gene have also been associated with specific somatic aberrations, including loss at the CDKN2A/B locus and allele specific loss of EGFR in the tumors. A specific TP53 low frequency variant has also been associated with glioma risk and validated in a separate data set. The genetic risk in the telomere regulating genes TERT and RTEL appear to be associated with higher grade tumors without IDH mutations. SUMMARY: The link of genetic loci to specific tumor subtypes may have relevance for understanding glioma biology, and for developing new diagnostic tools and targeted therapy for glioma.
Authors: Melissa L Bondy; Michael E Scheurer; Beatrice Malmer; Jill S Barnholtz-Sloan; Faith G Davis; Dora Il'yasova; Carol Kruchko; Bridget J McCarthy; Preetha Rajaraman; Judith A Schwartzbaum; Siegal Sadetzki; Brigitte Schlehofer; Tarik Tihan; Joseph L Wiemels; Margaret Wrensch; Patricia A Buffler Journal: Cancer Date: 2008-10-01 Impact factor: 6.860
Authors: Marc Sanson; Fay J Hosking; Sanjay Shete; Diana Zelenika; Sara E Dobbins; Yussanne Ma; Victor Enciso-Mora; Ahmed Idbaih; Jean-Yves Delattre; Khe Hoang-Xuan; Yannick Marie; Blandine Boisselier; Catherine Carpentier; Xiao-Wei Wang; Anna Luisa Di Stefano; Marianne Labussière; Konstantinos Gousias; Johannes Schramm; Anne Boland; Doris Lechner; Ivo Gut; Georgina Armstrong; Yanhong Liu; Robert Yu; Ching Lau; Maria Chiara Di Bernardo; Lindsay B Robertson; Kenneth Muir; Sarah Hepworth; Anthony Swerdlow; Minouk J Schoemaker; H-Erich Wichmann; Martina Müller; Stefan Schreiber; Andre Franke; Susanne Moebus; Lewin Eisele; Asta Försti; Kari Hemminki; Mark Lathrop; Melissa Bondy; Richard S Houlston; Matthias Simon Journal: Hum Mol Genet Date: 2011-04-29 Impact factor: 6.150
Authors: Sanjay Shete; Fay J Hosking; Lindsay B Robertson; Sara E Dobbins; Marc Sanson; Beatrice Malmer; Matthias Simon; Yannick Marie; Blandine Boisselier; Jean-Yves Delattre; Khe Hoang-Xuan; Soufiane El Hallani; Ahmed Idbaih; Diana Zelenika; Ulrika Andersson; Roger Henriksson; A Tommy Bergenheim; Maria Feychting; Stefan Lönn; Anders Ahlbom; Johannes Schramm; Michael Linnebank; Kari Hemminki; Rajiv Kumar; Sarah J Hepworth; Amy Price; Georgina Armstrong; Yanhong Liu; Xiangjun Gu; Robert Yu; Ching Lau; Minouk Schoemaker; Kenneth Muir; Anthony Swerdlow; Mark Lathrop; Melissa Bondy; Richard S Houlston Journal: Nat Genet Date: 2009-07-05 Impact factor: 38.330
Authors: Kyle M Walsh; Terri Rice; Paul A Decker; Matthew L Kosel; Thomas Kollmeyer; Helen M Hansen; Shichun Zheng; Lucie S McCoy; Paige M Bracci; Erik Anderson; George Hsuang; Joe L Wiemels; Alexander R Pico; Ivan Smirnov; Annette M Molinaro; Tarik Tihan; Mitchell S Berger; Susan M Chang; Michael D Prados; Daniel H Lachance; Hugues Sicotte; Jeanette E Eckel-Passow; John K Wiencke; Robert B Jenkins; Margaret R Wrensch Journal: Neuro Oncol Date: 2013-06-03 Impact factor: 12.300
Authors: Beatrice Melin; Anna M Dahlin; Ulrika Andersson; Zhaoming Wang; Roger Henriksson; Göran Hallmans; Melissa L Bondy; Christoffer Johansen; Maria Feychting; Anders Ahlbom; Cari M Kitahara; Sophia S Wang; Avima M Ruder; Tania Carreón; Mary Ann Butler; Peter D Inskip; Mark Purdue; Ann W Hsing; Leah Mechanic; Elizabeth Gillanders; Meredith Yeager; Martha Linet; Stephen J Chanock; Patricia Hartge; Preetha Rajaraman Journal: Int J Cancer Date: 2012-11-21 Impact factor: 7.396
Authors: Margaret Wrensch; Robert B Jenkins; Jeffrey S Chang; Ru-Fang Yeh; Yuanyuan Xiao; Paul A Decker; Karla V Ballman; Mitchel Berger; Jan C Buckner; Susan Chang; Caterina Giannini; Chandralekha Halder; Thomas M Kollmeyer; Matthew L Kosel; Daniel H LaChance; Lucie McCoy; Brian P O'Neill; Joe Patoka; Alexander R Pico; Michael Prados; Charles Quesenberry; Terri Rice; Amanda L Rynearson; Ivan Smirnov; Tarik Tihan; Joe Wiemels; Ping Yang; John K Wiencke Journal: Nat Genet Date: 2009-07-05 Impact factor: 38.330
Authors: V Enciso-Mora; F J Hosking; A L Di Stefano; D Zelenika; S Shete; P Broderick; A Idbaih; J-Y Delattre; K Hoang-Xuan; Y Marie; M Labussière; A Alentorn; P Ciccarino; M Rossetto; G Armstrong; Y Liu; K Gousias; J Schramm; C Lau; S J Hepworth; M Schoemaker; K Strauch; M Müller-Nurasyid; S Schreiber; A Franke; S Moebus; L Eisele; A Swerdlow; M Simon; M Bondy; M Lathrop; M Sanson; R S Houlston Journal: Br J Cancer Date: 2013-04-09 Impact factor: 7.640
Authors: Kelly M Macarthur; Gary D Kao; Sanjay Chandrasekaran; Michelle Alonso-Basanta; Christina Chapman; Robert A Lustig; E Paul Wileyto; Stephen M Hahn; Jay F Dorsey Journal: Cancer Res Date: 2014-02-13 Impact factor: 12.701
Authors: Barbara Heidenreich; P Sivaramakrishna Rachakonda; Ismail Hosen; Florian Volz; Kari Hemminki; Astrid Weyerbrock; Rajiv Kumar Journal: Oncotarget Date: 2015-04-30
Authors: Abigail Gabriel; Jason Batey; Joseph Capogreco; David Kimball; Andy Walters; R Shane Tubbs; Marios Loukas Journal: Med Sci Monit Date: 2014-08-25
Authors: Ali Jalali; E Susan Amirian; Matthew N Bainbridge; Georgina N Armstrong; Yanhong Liu; Spyros Tsavachidis; Shalini N Jhangiani; Sharon E Plon; Ching C Lau; Elizabeth B Claus; Jill S Barnholtz-Sloan; Dora Il'yasova; Joellen Schildkraut; Francis Ali-Osman; Siegal Sadetzki; Christoffer Johansen; Richard S Houlston; Robert B Jenkins; Daniel Lachance; Sara H Olson; Jonine L Bernstein; Ryan T Merrell; Margaret R Wrensch; Faith G Davis; Rose Lai; Sanjay Shete; Kenneth Aldape; Christopher I Amos; Donna M Muzny; Richard A Gibbs; Beatrice S Melin; Melissa L Bondy Journal: Sci Rep Date: 2015-02-05 Impact factor: 4.379
Authors: Sarah Hummel; Wendy Kohlmann; Thomas M Kollmeyer; Robert Jenkins; Joshua Sonnen; Cheryl A Palmer; Howard Colman; Diana Abbott; Lisa Cannon-Albright; Adam L Cohen Journal: BMC Cancer Date: 2019-03-01 Impact factor: 4.638